Background Left ventricular hypertrophy (LVH) is a common presentation among hypertensive patients. Micro-RNAs (miRNAs) have been proven to show reproducible dysregulations in hypertrophied cardiac tissues. Three miRNAs, miR-133, miR-155, and miR-195 were used in the study to elucidate the miRNA expression anomaly in heart diseases. MiR-133 and miR-195 have been reported as two highly expressed...

It is not easy to define the mechanism of hypertrophy in he average blood pressure (BP) level has certainly decreased in Japan since 1960,1 but the prevalence of hypertension (HT) may be on the rise in the next 2–3 decades. When considering national healthcare costs, the treatment of HT and prevention of related diseases is crucial. The target of treatment is to lower BP in patients with HT, pr...

Background—Left ventricular hypertrophy (LVH) is traditionally classified as concentric or eccentric, based on the ratio of LV wall thickness to chamber dimension. We propose a 4-tiered LVH classification based on LV concentricity (mass/end-diastolic volume) and indexed LV end-diastolic volume (EDV). Methods and Results—Cardiac MRI was performed in 2803 subjects and LVH (n 895) was defined by i...

INTRODUCTION Long-lasting arterial hypertension causes left ventricular hypertrophy (LVH) and impairs left ventricular diastolic function. Our aim was to compare echocardiographic parameters between hypertensive patients defined as dippers and non-dippers during ambulatory blood pressure (BP) monitoring. MATERIAL AND METHODS We analysed 61 consecutive subjects with treated hypertension underg...

Cardiovascular disease is a major cause of death among patients with chronic kidney disease and vitamin D deficiency is a common problem also among these patients. Abnormalities in left ventricular size and function are frequent, as they are encountered in 70-80% of incident dialysis patients. These alterations develop early in the course of renal disease and their prevalence progresses in para...

BACKGROUND Hyperinsulinemia and insulin resistance are associated with left ventricular hypertrophy (LVH) and cardiovascular complications in hypertensive subjects. The aim of this study was to explore the mechanisms for LVH including activation of the renin-angiotensin system system (RAS) and the sympathetic nervous system and their activation by insulin using a rat model of hyperinsulinemia a...

OBJECTIVES Increased arterial stiffness is associated with left ventricular diastolic dysfunction (LVDD), but this association may be influenced by left ventricular (LV) performance. Left ventricular hypertrophy (LVH) is not only a significant determinant of LV performance, but is also correlated with LVDD. This study is designed to compare LV diastolic function among patients divided by brachi...

We investigated the effects of 17-methoxyl-7-hydroxy-benzene-furanchalcone (MHBFC), which was isolated from the roots of Millettia pulchra (Benth.) Kurz var. Laxior (Dunn) Z.Wei (Papilionaceae) (MKL), on the progression of cardiac hypertrophy to failure in a rat model of abdominal aortic banding (AAB)-induced pressure overloading. Endothelial dysfunction is central to pressure overload-induced ...

Current research in left ventricular hypertrophy (LVH) has largely focused on its progression and therapeutic mechanisms to prevent or slow its development. Few studies have centered on the regression or treatment of existing LVH. Nuclear factor-kappaB (NF-kappaB) is an inflammatory transcription factor that has been shown to be involved in LVH development. We hypothesized that proteasome-media...

OBJECTIVE—Left ventricular hypertrophy (LVH), an independent risk factor for cardiovascular (CV) morbidity and mortality, recognizes a multifactorial pathogenesis. A plasma glucose value $155 mg/dL for the 1-h postload plasma glucose during an oral glucose tolerance test (OGTT) identifies subjects with normal glucose tolerance (NGT) at high risk for type 2 diabetes. We addressed the question if...